Sanofi (SNY) shares soared 6.7% in the last trading session to close at $48.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 5.4% loss over the past four weeks.This jump in share price came after management reported positive results from a mid-stage study on its experimental anti-TL1A therapy, duvakitug, in Ulcerative Colitis and Crohn's disease, which are the two main types of inflammatory bowel disease. The study achieved it ...

Key TakeawaysTeva Pharmaceuticals and Sanofi on Tuesday reported positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn's disease.The companies plan to provide further details about the research at a scientific forum in 2025.Teva and Sanofi said they would start a Phase 3 study of the treatment pending discussions with regulators.Both pharmaeuticals companies' U.S.-traded stocks gained after the news Tuesday, with Teva at its highest level in six years. U.S.-traded shares of Tev ...

On Tuesday, Teva Pharmaceutical Industries Ltd. TEVA and Sanofi SA’s SNY Phase 2b RELIEVE UCCD study met its primary endpoints in patients with ulcerative colitis (UC) and Crohn’s disease (CD).RELIEVE UCCD investigated duvakitug (TEV’574/SAR447189), a human IgG1-λ2 monoclonal antibody targeting TL1A, for moderate-to-severe inflammatory bowel disease (IBD).In the RELIEVE UCCD study, 36.2% (low-dose) and 47.8% (high-dose) of patients with ulcerative colitis treated with duvakitug achieved clinical remission c ...

Duvakitug positive phase 2b results demonstrate best-in-class potential in ulcerative colitis and Crohn’s disease Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate phase 3 development in IBD, pending regulatory discussionsProgram underscores Sanofi's Immunology leadership ambitio ...

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD)Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibodySanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanof ...

Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis Designation is based on positive results from the HERCULES study in adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS)Tolebrutinib is the first and only brain-penetrant BTK inhibitor in MS to be designated Breakthrough Therapy by the FDA  Paris, December 13, 2024. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for ...

Availability of the revised financial statements for Sanofi excluding Opella Paris, France – December 6, 2024. Following the press release on October 21, 2024 and the plan to transfer a 50% controlling stake in Opella (consumer healthcare division) to CD&R, the revised financial statements for Sanofi reflecting the new scope, excluding Opella, are now available on the "Investors" section of sanofi.com in one convenient spreadsheet file. The adjustments to the financial statements reclassify Opella’s busines ...

BEIJING, Dec. 04, 2024 (GLOBE NEWSWIRE) -- The global pharmaceutical giant Sanofi has once again boosted its investment in Beijing E-Town. On December 2nd, the Administrative Committee of the Beijing Economic-Technological Development Area (BDA) and Sanofi formally signed a memorandum of cooperation. Sanofi will invest approximately 1 billion euros to establish a new insulin production facility in Beijing E-Town, enhancing local end-to-end manufacturing capabilities for insulin and primarily serving the nee ...

新华社北京12月2日电（记者郭宇靖）记者从北京经济技术开发区了解到，2日，北京市经济和信息化 局、北京经济技术开发区管委会与国际知名药企赛诺菲正式签署合作备忘录，赛诺菲将投资约10亿欧 元，在北京亦庄新建胰岛素生产基地。这将是赛诺菲在华第四个生产供应基地，并创造该公司在华最大 单笔投资纪录。 此次新设立的胰岛素生产基地将主要生产胰岛素生物制剂活性物质，为赛诺菲北京工厂现有胰岛素制剂 产品供给生物原料。赛诺菲首席执行官韩保罗表示，通过采用高标准的自动化生产方式、一流的数字化 综合管理和可持续的环保标准，新的生产基地将进一步帮助公司增强供应链韧性，更高效地满足不断增 长的糖尿病患者需求。 赛诺菲董事会主席弗雷德里克·乌代阿表示，赛诺菲坚定看好中国市场长期发展，中国秉持的对外开放 和鼓励创新的政策，以及为外资企业营造的良好营商环境，为赛诺菲深度参与中国经济发展、助力医药 产业高质量发展注入了强大信心。 北京经开区有关负责人表示，将持续优化营商环境，营造开放包容的产业生态，支持跨国药企选择北 京、投资亦庄，共绘医药健康产业发展新蓝图。 赛诺菲是一家总部位于法国的跨国制药企业，目前在国内拥有多家生产基地和研发基地。其中 ...

A Sanofi logo sits on the facade of the company's headquarters on December 11, 2020 in Gentilly near Paris, France.SINGAPORE — French pharmaceutical giant Sanofi on Wednesday opened a 800 million Singapore dollar ($595 million) "evolutive vaccine facility," or EVF, in Singapore — the only such facility the company has outside of France.This plant, known as Modulus, can switch between making different vaccines or treatments in a matter of days, compared to several weeks or months in more conventional facilit ...